Stand Up To Cancer - standup2cancer.orgThis is where the end of cancer begins
   Please leave this field empty

In The News

Share this:

Like this page on Facebook

SU2C scientists probe patient response to cancer immunotherapy

In research supported by SU2C, F. Stephen Hodi, MD, of the Dana-Farber Cancer Institute and colleagues investigated whether a serumbiomarker could predict the response of patients receiving immune checkpoint inhibitors, a type of immunotherapy. This is very important to improving the utilization ofimmunotherapies. According to a paper published in a journal published by SU2C’s Scientific Partner, the American Association for Cancer Research, Hodi’s team found that serum levels of a protein called ANGPT2 predicted response to, and influenced the outcomes of,immune checkpoint inhibitors in patients with advanced melanoma.

+ More

Scientific Advisory Committee member, Dr. David Tuveson, named director of Cold Spring Harbor cancer

David Tuveson, MD, PhD, a leader in pancreatic cancer research, and member of SU2C’s Scientific Advisory Committee has been named the new director of CSHL’s cancer center, a National Cancer Institute (NCI)-designated research facility. In addition to his roles at Cold Spring Harbor Lab, where he is a professor, and as one of our SU2C scientific leaders, Tuveson is a clinician who treats pancreatic cancer patients at Memorial Sloan Kettering Cancer Center and is Director of Research for SU2C collaborator, the Lustgarten Foundation for Pancreatic Research.

+ More

SU2C scientist named a 2016 Giant of Cancer Care

Dr. Daniel Von Hoff, physician-in-chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) at Mayo Clinic and leader of the SU2C-CRUK-Lustgarten Foundation Pancreatic Cancer Dream Team, was named a 2016 Giant of Cancer Care. This prestigious award honors the achievements of exceptional leaders in the field of oncology research and clinical practice.

+ More

MLB takes a break during the 2016 World Series to Stand Up To Cancer

Major League Baseball takes a break during the 2016 World Series to Stand Up To Cancer

+ More

SU2C-supported researchers find novel strategy in combination drug therapy

A research team supported in part by SU2C has published findings that show how we may be able to kill cancerous cells more effectively by combining drugs that work together to significantly disrupt a cancer cell’s ability to survive DNA damage. These findings are the first to show this combination drug therapy as a novel approach for treating acute myeloid leukemia (AML) and potentially, many other cancers.

+ More

Innovate Collaborate Accelerate
This year, approximately 1.65 million Americans will be diagnosed with cancer and about 585,720 will die of the disease.